Breaking News

AGC Biologics to Manufacture Orchard Therapeutics’ Lenmeldy

AGC’s Milan site now has clearances from both U.S. and European regulators to supply the HSC-based gene therapy using approved commercial processes.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical CDMO, today announced that the U.S. FDA has cleared its Milan site to begin commercial manufacturing for the lentiviral vector and genetically modified cell drug product (DP) of Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy for the treatment of pre-symptomatic late infantile, pre-symptomatic early juvenile and early symptomatic early juvenile metachromatic leukodystrophy (MLD). Lenmeldy received ap...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters